PDCD1 and neoplasm: By day 21 all eight mice treated with the combination of anti-PD-1 plus 20 μg VB-85247 displayed robust tumor control, whereas only six of eight mice receiving 20 μg VB-85247 with the isotype antibody displayed similar efficacy, suggesting the potential of combination therapy for more rapid efficacy.